Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer

Despite  improvements in outcome, 15-25% of newly diagnosed multiple myeloma (MM) patients have treatment resistant high-risk (HR) disease with a poor survival. The lack of a genetic basis for HR has focused attention on the role played by epigenetic changes. Aberrant expression and somatic mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghamlouch, Hussein, Boyle, Eileen M., Blaney, Patrick, Wang, Yubao, Choi, Jinyoung, Williams, Louis, Bauer, Michael, Auclair, Daniel, Bruno, Benedetto, Walker, Brian A., Davies, Faith E., Morgan, Gareth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638425/
https://www.ncbi.nlm.nih.gov/pubmed/34857028
http://dx.doi.org/10.1186/s13046-021-02185-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638425/
https://www.ncbi.nlm.nih.gov/pubmed/34857028
http://dx.doi.org/10.1186/s13046-021-02185-1

Ejemplares similares